• 대한약리학회지
• /
• 제16권2호
• /
• pp.55-70
• /
• 1980

The pharmacological and microbiological studies of Cefoperazone (T-1551, Toyama Chemical Co., Japan) were conducted in vitro and in vivo. The studies included stability and physicochemical characteristics, antimicrobial activity, animal and human pharmacokinetics, animal pharmacodynamics and safety evaluation of Cefoperazone sodium for injection. 1) Stability and physicochemical characteristics. Sodium salt of cefoperazone for injection had a general appearance of white crystalline powder which contained 0.5% water, and of which melting point was $187.2^{\circ}C$. The pH's of 10% and 25% aqueous solutions were 5.03 ana 5.16 at $25^{\circ}C$. The preparations of cefoperazone did not contain any pyrogenic substances and did not liberate histamine in cats. The drug was highly compatible with common infusion solutions including 5% Dextrose solution and no significant potency decrease was observed in 5 hours after mixing. Powdered cefoperazone sodium contained in hermetically sealed and ligt-shielded container was highly stable at $4^circ}C{\sim}37^{\circ}C$ for 12 weeks. When stored at $4^{\circ}C$ the potency was retained almost completely for up to one year. 2) Antimicrobial activity against clinical isolates. Among the 230 clinical isolates included, Salmonella typhi was the most susceptible to cefoperazone, with 100% inhibition at MIC of ${\leq}0.5{\mu}g/ml$. Cefoperazone was also highly active against Streptococcus pyogenes(group A), Kletsiella pneumoniae, Staphylococcus aureus and Shigella flexneri, with 100% inhibition at $16{\mu}g/ml$ or less. More than 80% of Escherichia coli, Enterobacter aerogenes and Salmonella paratyphi was inhibited at ${\leq}16{\mu}/ml$, while Enterobacter cloaceae, Serratia marcescens and Pseudomonas aerogenosa were somewhat less sensitive to cefoperagone, with inhibitions of 60%, 55% and 35% respectively at the same MIC. 3) Animal pharmacokinetics Serum concentration, organ distritution and excretion of cefoperazone in rats were observed after single intramuscular injections at doses of 20 mg/kg and 50 mg/kg. The extent of protein binding to human plasma protein was also measured in vitro br equilibrium dialysis method. The mean Peak serum concentrations of $7.4{\mu}g/ml$ and $16.4{\mu}/ml$ were obtained at 30 min. after administration of cefoperazone at doses of 20 mg/kg and 50 mg/kg respectively. The tissue concentrations of cefoperazone measured at 30 and 60 min. were highest in kidney. And the concentrations of the drug in kidney, liver and small intestine were much higher than in blood. Urinary and fecal excretion over 24 hours after injetcion ranged form 12.5% to 15.0% in urine and from 19.6% to 25.0% in feces, indicating that the gastrointestinal system is more important than renal system for the excretion of cefoperazone. The extent of binding to human plasma protein measured by equilibrium dialysis was $76.3%{\sim}76.9%$, which was somewhat lower than the others utilizing centrifugal ultrafiltration method. 4) Animal pharmacodynamics Central nervous system : Effects of cefoperazone on the spontaneous movement and general behavioral patterns of rats, the pentobarbital sleeping time in mice and the body temperature in rabbits were observed. Single intraperitoneal injections at doses of $500{\sim}2,000mg/kg$ in rats did not affect the spontaneous movement ana the general behavioral patterns of the animal. Doses of $125{\sim}500mg/kg$ of cefoperazone injected intraperitonealy in mice neither increased nor decreased the pentobarbital-induced sleeping time. In rabbits the normal body temperature was maintained following the single intravenous injections of $125{\sim}2,000mg/kg$ dose. Respiratory and circulatory system: Respiration rate, blood pressure, heart rate and ECG of anesthetized rabbits were monitored for 3 hours following single intravenous injections of cefoperazone at doses of $125{\sim}2,000mg/kg$. The respiration rate decreased by $3{\sim}l7%$ at all the doses of cefoperazone administered. Blood pressure did not show any changes but slight decrease from 130/113 to 125/107 by the highest dose(2,000 mg/kg) injected in this experiment. The dosages of 1,000 and 2,000 mg/kg seemed to slightly decrease the heart rate, but it was not significantly different from the normal control. All the doses of cefoperazone injected were not associated with any abnormal changes in ECG findings throughout the monitering period. Autonomic nervous system and smooth muscle: Effects of cefoperazone on the automatic movement of rabbit isolated small intestine, large intestine, stomach and uterus were observed in vitro. The autonomic movement and tonus of intestinal smooth muscle increased at dose of $40{\mu}g/ml$ in small intestine and at 0.4 mg/ml in large intestine. However, in stomach and uterine smooth muscle the autonomic movement was slightly increased by the much higher doses of 5-10 mg/ml. Blood: In vitro osmotic fragility of rabbit RBC suspension was not affected by cefoperazone of $1{\sim}10mg/ml$. Doses of 7.5 and 10 mg/ml were associated with 11.8% and 15.3% prolongation of whole blood coagulation time. Liver and kidney function: When measured at 3 hours after single intravenous injections of cefoperaonze in rabbits, the values of serum GOT, GPT, Bilirubin, TTT, BUN and creatine were not significantly different from the normal control. 5) Safety evaluation Acute toxicity: The acute toxicity of cefoperazone was studied following intraperitoneal and intravenous injections to mice(A strain, 4 week old) and rats(Sprague-Dawler, 6 week old). The LD_(50)'s of intraperitonealy injected cefoperazone were 9.7g/kg in male mice, 9.6g/kg in female mice and over 15g/kg in both male and female rats. And when administered intravenously in rats, LD_(50)'s were 5.1g/kg in male and 5.0g/kg in female. Administrations of the high doses of the drug were associated with slight inhibition of spontaneous movement and convulsion. Atdominal transudate and intestinal hyperemia were observed in animals administered intraperitonealy. In rats receiving high doses of the drug intravenously rhinorrhea and pulmonary congestion and edema were also observed. Renal proximal tubular epithelial degeneration was found in animals dosing in high concentrations of cefoperazone. Subacute toxicity: Rats(Sprague-Dawley, 6 week old) dosing 0.5, 1.0 and 2.0 g/kg/day of cefoperazone intraperitonealy were observed for one month and sacrificed at 24 hours after the last dose. In animals with a high dose, slight inhibition of spontaneous movement was observed during the experimental period. Soft stool or diarrhea appeared at first or second week of the administration in rats receiving 2.0g/kg. Daily food consumption and weekly weight gain were similar to control during the administration. Urinalysis, blood chemistry and hematology after one month administration were not different from control either. Cecal enlargement, which is an expected effect of broad spectrum antibiotic altering the normal intestinal microbial flora, was observed. Intestinal or peritoneal congestion and peritonitis were found. These findings seemed to be attributed to the local irritation following prolonged intraperitoneal injections of hypertonic and acidic cefoperazone solution. Among the histopathologic findings renal proximal tubular epithelial degeneration was characteristic in rats receiving 1 and 2g/kg/day, which were 10 and 20 times higher than the maximal clinical dose (100 mg/kg) of the drug. 6) Human pharmacokinetics Serum concentrations and urinary excretion were determined following a single intravenous injection of 1g cefoperazone in eight healthy, male volunteers. Mean serum concentrations of 89.3, 61.3, 26.6, 12.3, 2.3, and $1.8{\mu}g/ml$ occured at 1,2,4,6,8 and 12 hours after injection respectively, and the biological half-life was 108 minutes. Urinary excretion over 24 hours after injection was up to 43.5% of administered dose.

• 대한화장품학회지
• /
• 제30권2호
• /
• pp.263-278
• /
• 2004

Ursolic acid (UA)와 oleanolic acid (ONA)는 pentacyclic triterpenoid 성분으로 많은 식물들과 의학, 임상용 허브 등에 존재한다. 이런 UA나 ONA는 free acid 형태로 나타나거나, 1개 이상의 당이 연결된 aglycone으로 triterpenoid 배당체를 구성한다. UA와 ONA는 유사한 구조를 가지며 비슷한 약리효과를 나타내는 것으로 알려져 있다. 최근 연구에 의하면, 항종양, 간보호, 항염증, 함암 및 항균역할을 하는 것으로 보고되고 있다. 우리는 급성 장벽손상 및 정상 무모쥐 피부에 미치는 영항에 대한 연구를 했다. UA와 ONA의 피부장벽 회복에 대한 효과를 평가하기 위해서, 8-12주 된 무모쥐를 테이프 스트리핑 한 후, 한쪽 옆구리에 0.01 -0.1mg/mL 농도로 UA 또는 ONA를 국소도포하고 한쪽에는 vehicle만 처치하여 경표피 수분손실(TEWL)량을 측정하였다. UA (0.1mg/mL)와 ONA (0.5mg/mL)를 처리한 그룹의 회복률이 vehicle 처리군에 비해 테이프 스트리핑 후 6 h에서 20% 이상 증가했다.(p < 0.01). 또한 UA와 ONA의 급성장벽손상 회복과 함께 정상 피부장벽 기능에 미치는 영향을 확인하였다. 정상 피부장벽 기능에 대한 효과를 알아보기 위해, 보습력과 경표피 수분손실량을 UA와 ONA (각 2 mg/mL)를 처리한 1주째와 3주째에 측정하였고, 또한 표피와 진피의 상태를 확인하기 위해서 현미경 관찰을 실시하였다. 두 시료를 1주째부터 vehicle 도포군과 비교, 경표피 수분손실 없이 보습력을 증가시켰다(p < 0.005). 전자현미경 사진을 통해 UA와 ONA 도포에 따라 분비되는 층판소체의 증감(ONA$\geq$UA$\geq$vehicle)과 지질이중막 구조 이상 여부를 확인하였다 Light microscopy를 통해 각질층의 두께가 약간 증가함을 보였으며, 특히 표피두께 강화와 편평 현상이 나타났다(UA < ONA < Vehicle). 우리는 또한 UA와 ONA가 PPAR $\alpha$를 통해 표피 각질세포의 분화를 촉진함을 관찰하였다. Western blotting 실험을 통해, 표피 각질세포 분화와 관련된 involucrin, loricrin, filaggrin의 단백질 발현이 최소한 2-3배 이상 증가함을 HaCaT 세포에 UA와 ONA(각 10$\mu$M)를 24 h 처리 후 실험 결과로 확인할 수 있었다. 이런 결과를 토대로 UA와 ONA가 장벽기능 향상뿐 아니라 PPAR $\alpha$를 통한 표피 각질세포 분화를 유도함을 제시할 수 있었다. Masson-trichrome과 elastic fiber 염색법을 통해서, UA와 ONA 도포에 따른 콜라겐섬유의 비후(thickening)와 엘라스틴섬유의 신장(elongation)을 조직 사진으로 확인하였다. 시험관 시험을 통한 콜라겐 및 엘라스틴 합성실험과 엘라스틴 분해효소에 대한 저해능 평가를 통해 진피에 대한 UA와 ONA의 효과를 확인할 수 있었다. 이런 결과들을 토대로 UA와 ONA는 피부장벽기능 유지뿐 아니라, 진피 내 콜라겐섬유와 엘라스틴섬유 합성을 촉진하는 것을 관찰할 수 있었다. 이 결과로부터, UA와 ONA는 장벽기능 및 진피강화에 관여할 수 있는 기능성 화장품으로의 응용에 적절한 후보 물질로 제안할 수 있겠다.